Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer immunotherapeutics - Akamis Bio

Drug Profile

Research programme: cancer immunotherapeutics - Akamis Bio

Alternative Names: AbEnAds; anti-human VEGF armed EnAd; anti-PDL1 AbEnAds; NG 345; NG 347; NG 600; NG aEpCAM; NG aFAP; NG-600 series

Latest Information Update: 28 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PsiOxus Therapeutics
  • Developer Akamis Bio
  • Class Antibodies; Antineoplastics; Bispecific antibodies; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Epithelial cell adhesion molecule inhibitors; Fibroblast activation protein antagonists; Gene transference; Immunomodulators; Immunostimulants; Programmed cell death-1 ligand-1 inhibitors; Vascular endothelial growth factors modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Dec 2023 No recent reports of development identified for preclinical development in Solid-tumours in United Kingdom (Intratumoural, Injection)
  • 05 Jan 2023 PsiOxus Therapeutics is now called Akamis Bio
  • 10 Apr 2021 Preclinical pharmacodynamic presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top